Objective: Vulval cancer account for 5% of gynaecological malignancies worldwide with 1400 new cases diagnosed in the UK every year. VIN is a premalignant condition that requires appropriate identification and treatment to prevent progression to vulval cancer. The standard treatment for VIN/vulval cancer is surgical and can result in considerable morbidity, therefore alternative treatments have been sought. Plasmajet ® is a surgical energy device that utilises neutral argon plasma to ablate tissue. This UK-based study includes the largest cohort of patients to date with VIN who have undergone Plasmajet ® treatment and attempts to lay a foundation for understanding the impact of this novel treatment. Design: Single centre retrospective observational study over ten-year study period. Setting: Gynaecological Cancer Centre, London, England. Population: All women with VIN 1-3 treated with Plasmajet® between September 2014 and March 2024 inclusive. Methods: Data on demographics, background, treatment, complications, and outcome, was collected from electronic medical records and analysed using Microsoft Excel. Main Outcome Measures: Treatment, complications, and outcome. Results: Forty-six patients were included; the majority had high-grade VIN; 18 patients (39%) had VIN 3, 12 patients (26%) had VIN 2/3 and five patients (11%) had VIN 2. 127 Plasmajet ® treatments were administered; seven patients (15%) had disease progression, 21 (46%) remain under active surveillance without evidence of progression, 12 (26%) have been discharged with the remaining lost to follow-up. Complication rates were 7%. Conclusions: This study has shown the potential efficacy and safety profile of Plasmajet ® in the largest cohort of patients with VIN to date.